With the renewed recognition of DHODH’s role in ferroptosis, brequinar or its liposome has resurfaced as a promising candidate for combination therapy in resistant tumors such as glioblastoma, colorectal cancer, and hepatocellular carcinoma [13,14,74,76]. This evidence concerns the gene DHODH and hepatocellular carcinoma.